Adial Pharmaceuticals(ADIL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ADIL Adial Pharmaceuticals

Not Yet Opened 02-04 16:00:00 EST

0.1568

-0.0545

-25.79%

盘后0.1568

+0.00000.00%

19:51 EST

High0.1700	Low0.1525	Vol3.22M
Open0.1700	D1 Closing0.2113	Amplitude8.28%
Mkt Cap4.36M	Tradable Cap4.16M	Total Shares27.78M
T/O521.15K	T/O Rate12.15%	Tradable Shares26.54M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ADIL","market":"US","secType":"STK","nameCN":"Adial Pharmaceuticals","latestPrice":0.1568,"timestamp":1770238800000,"preClose":0.2113,"halted":0,"volume":3224752,"hourTrading":{"tag":"盘后","latestPrice":0.1568,"preClose":0.1568,"latestTime":"19:51 EST","volume":83359,"amount":13219.07235,"timestamp":1770252672313,"change":0,"changeRate":0,"amplitude":0.079082},"delay":0,"changeRate":-0.2579271178419309,"floatShares":26541000,"shares":27779300,"eps":-0.9289,"marketStatus":"Not Yet Opened","change":-0.0545,"latestTime":"02-04 16:00:00 EST","open":0.17,"high":0.17,"low":0.1525,"amount":521147.23684944,"amplitude":0.082821,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-0.9289,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1770282000000},"marketStatusCode":0,"adr":0,"adrRate":0,"listingDate":1532664000000,"exchange":"NASDAQ","adjPreClose":0.2113,"preHourTrading":{"tag":"盘前","latestPrice":0.1719,"preClose":0.2113,"latestTime":"09:29 EST","volume":167006,"amount":28621.99263812,"timestamp":1770215344311,"change":-0.0394,"changeRate":-0.186465,"amplitude":0.033602},"postHourTrading":{"tag":"盘后","latestPrice":0.1568,"preClose":0.1568,"latestTime":"19:51 EST","volume":83359,"amount":13219.07235,"timestamp":1770252672313,"change":0,"changeRate":0,"amplitude":0.079082},"volumeRatio":10.385541,"impliedVol":1.6275,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/ADIL/tweets","defaultTab":"tweets","newsList":[{"id":"2609319283","title":"Adial Pharmaceuticals Implements Reverse Stock Split to Regain Compliance","url":"https://stock-news.laohu8.com/highlight/detail?id=2609319283","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609319283?lang=en_us&edition=fundamental","pubTime":"2026-02-05 06:11","pubTimestamp":1770243107,"startTime":"0","endTime":"0","summary":"Adial Pharmaceuticals ( ($ADIL) ) has shared an announcement. On August 1, 2025, shareholders of Adial Pharmaceuticals approved a reverse stock spl...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/adial-pharmaceuticals-implements-reverse-stock-split-to-regain-compliance?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/adial-pharmaceuticals-implements-reverse-stock-split-to-regain-compliance?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ADIL","BK4007"],"gpt_icon":0},{"id":"2608398294","title":"Adial Applauds Congressional Directive Advancing Alternative Clinical Trial Endpoints for Substance Use Disorders, Strengthening Regulatory Path for AD04","url":"https://stock-news.laohu8.com/highlight/detail?id=2608398294","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608398294?lang=en_us&edition=fundamental","pubTime":"2026-02-04 22:35","pubTimestamp":1770215700,"startTime":"0","endTime":"0","summary":"GLEN ALLEN, Va., Feb.  04, 2026  (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies f","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/04/3232184/26135/en/Adial-Applauds-Congressional-Directive-Advancing-Alternative-Clinical-Trial-Endpoints-for-Substance-Use-Disorders-Strengthening-Regulatory-Path-for-AD04.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ADIL"],"gpt_icon":0},{"id":"2608800691","title":"Adial Pharmaceuticals Inc - Announces 1-for-25 Reverse Stock Split","url":"https://stock-news.laohu8.com/highlight/detail?id=2608800691","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608800691?lang=en_us&edition=fundamental","pubTime":"2026-02-04 05:05","pubTimestamp":1770152701,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nTUA4R3QQ6:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ADIL","BK4007"],"gpt_icon":0},{"id":"2608800261","title":"Adial Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Minimum Bid Price Requirement","url":"https://stock-news.laohu8.com/highlight/detail?id=2608800261","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608800261?lang=en_us&edition=fundamental","pubTime":"2026-02-04 05:05","pubTimestamp":1770152700,"startTime":"0","endTime":"0","summary":"Common Stock Will Begin Trading on Split-Adjusted Basis on February 6, 2026GLEN ALLEN, Va., Feb.  03, 2026  (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL)(“Adial” or the “Company”), a ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/03/3231596/26135/en/Adial-Pharmaceuticals-Announces-Reverse-Stock-Split-to-Regain-Compliance-with-Nasdaq-s-Minimum-Bid-Price-Requirement.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ADIL"],"gpt_icon":0},{"id":"2603612825","title":"Adial Pharmaceuticals Announces Publication of International PCT Patent Application to Protect Core Assets and Extend IP Exclusivity to at least 2045","url":"https://stock-news.laohu8.com/highlight/detail?id=2603612825","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603612825?lang=en_us&edition=fundamental","pubTime":"2026-01-14 22:00","pubTimestamp":1768399200,"startTime":"0","endTime":"0","summary":"New patent based on treatment of populations identified to be particularly responsive to ondansetron treatment after examination of Adial’s clinical data and informationGLEN ALLEN, Va., Jan.  14, 2026","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/14/3218692/26135/en/Adial-Pharmaceuticals-Announces-Publication-of-International-PCT-Patent-Application-to-Protect-Core-Assets-and-Extend-IP-Exclusivity-to-at-least-2045.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IP","BK4585","LU2463526074.USD","IE00B3T34201.USD","LU1487256676.USD","BK4136","LU1481599808.USD","PCT","BK4588","LU1169589451.USD","LU1481600234.SGD","BK4007","ADIL","LU1169590202.USD","BK4090"],"gpt_icon":0},{"id":"2601284331","title":"Adial Pharmaceuticals Director James W. Newman Jr. Resigns","url":"https://stock-news.laohu8.com/highlight/detail?id=2601284331","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601284331?lang=en_us&edition=fundamental","pubTime":"2026-01-07 05:16","pubTimestamp":1767734197,"startTime":"0","endTime":"0","summary":"Adial Pharmaceuticals Inc. announced that James W. Newman, Jr. has resigned from the company's Board of Directors, effective immediately. Newman also stepped down from his roles on the Audit Committee and the Compensation Committee. No disagreements with the company were reported.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adial Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 06, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nNDL9mCQQQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ADIL"],"gpt_icon":0},{"id":"2593448755","title":"Adial Pharmaceuticals Inc. Announces Date for Upcoming Special Stockholders Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2593448755","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593448755?lang=en_us&edition=fundamental","pubTime":"2025-12-24 05:01","pubTimestamp":1766523692,"startTime":"0","endTime":"0","summary":"Adial Pharmaceuticals Inc. has scheduled a special meeting of stockholders on February 26, 2026. Stockholders will be asked to vote on Proposal Nos. 1 and 2, as recommended by the Board of Directors.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adial Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 23, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251223:nNDLbfq4Z4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ADIL"],"gpt_icon":0},{"id":"2586025760","title":"Adial Pharmaceuticals announces $2.86M warrant inducement transaction","url":"https://stock-news.laohu8.com/highlight/detail?id=2586025760","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586025760?lang=en_us&edition=fundamental","pubTime":"2025-11-26 21:05","pubTimestamp":1764162342,"startTime":"0","endTime":"0","summary":"Adial Pharmaceuticals (ADIL) announced its entry into a warrant inducement agreement with an existing healthcare-focused institutional investor of ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/adial-pharmaceuticals-announces-2-86m-warrant-inducement-transaction-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/adial-pharmaceuticals-announces-2-86m-warrant-inducement-transaction-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","ADIL"],"gpt_icon":0},{"id":"2586299252","title":"Adial Pharmaceuticals Announces a Warrant Inducement Transaction for Approximately $2.86 Million in Gross Proceeds","url":"https://stock-news.laohu8.com/highlight/detail?id=2586299252","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586299252?lang=en_us&edition=fundamental","pubTime":"2025-11-26 21:00","pubTimestamp":1764162000,"startTime":"0","endTime":"0","summary":"GLEN ALLEN, Va., Nov.  26, 2025  (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies f","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/26/3195096/26135/en/Adial-Pharmaceuticals-Announces-a-Warrant-Inducement-Transaction-for-Approximately-2-86-Million-in-Gross-Proceeds.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ADIL"],"gpt_icon":0},{"id":"2584954103","title":"Strategic Advancements and Collaborations Propel Adial Pharmaceuticals’ Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2584954103","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584954103?lang=en_us&edition=fundamental","pubTime":"2025-11-19 00:45","pubTimestamp":1763484323,"startTime":"0","endTime":"0","summary":"Jason McCarthy, an analyst from Maxim Group, maintained the Buy rating on Adial Pharmaceuticals. The associated price target remains the same with ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/strategic-advancements-and-collaborations-propel-adial-pharmaceuticals-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/strategic-advancements-and-collaborations-propel-adial-pharmaceuticals-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ADIL"],"gpt_icon":0},{"id":"2584644000","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2584644000","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584644000?lang=en_us&edition=fundamental","pubTime":"2025-11-17 19:00","pubTimestamp":1763377200,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·J & J Snack Fds                                 4Q      1.24        BMO","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BULL","CING","AS","CLCO","ENTA","ATRA","BRBR","CRGO","AHL","ENR","NVDA","ALLT","ACM","CDLR","DLB","WB","CPRT","NTES","ARMK","BNTC","CRNC","VIPS","XP","ATOS","AZTA","CRDL","DE","DY","CLSD","ADIL","ZTO","CGON","WMT","BMA","CPA","EARN","TBBB","AREC","BV","BZ","POWL","TGT","ATKR","BBWI","ARBE","TCOM","ANRO"],"gpt_icon":1},{"id":"2583722509","title":"Adial Pharmaceuticals reports Q3 net loss of $1.8 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2583722509","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583722509?lang=en_us&edition=fundamental","pubTime":"2025-11-14 21:36","pubTimestamp":1763127364,"startTime":"0","endTime":"0","summary":"Adial Pharmaceuticals reported a net loss of $1.8 million for the third quarter of 2025, compared to a net loss of $2.2 million for the same period in 2024. Research and development expenses decreased by approximately $0.5 million, or 50%, due to lower clinical activity. General and administrative expenses increased by about $0.1 million, or 5%, mainly due to the timing of the company's annual meeting. Cash and cash equivalents were $4.6 million as of September 30, 2025, down from $5.9 million as of June 30, 2025. The company expects its current cash position to fund operations into the second quarter of 2026. Business developments included the filing of an updated provisional patent application for AD04, its lead investigational drug for Alcohol Use Disorder, and progress toward FDA approval.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nNDL9gcGGK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADIL","BK4007"],"gpt_icon":0},{"id":"2583509232","title":"Adial Pharmaceuticals Q3 Net Income USD -1.8 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2583509232","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583509232?lang=en_us&edition=fundamental","pubTime":"2025-11-14 21:30","pubTimestamp":1763127002,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nPLX53DEB6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ADIL"],"gpt_icon":0},{"id":"2583501680","title":"Adial Pharmaceuticals: Implementing FDA's Recommendations Based on Eop2 Meeting, to Advance Ad04 Toward Phase 3 Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2583501680","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583501680?lang=en_us&edition=fundamental","pubTime":"2025-11-14 21:30","pubTimestamp":1763127002,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nTUA8PQRGB:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ADIL"],"gpt_icon":0},{"id":"2583980577","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2583980577","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583980577?lang=en_us&edition=fundamental","pubTime":"2025-11-14 19:00","pubTimestamp":1763118000,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·Li Auto Inc. Sp ADR                               3Q       .10. ·J & J Snack Fds                                 4Q      1.24        BMO","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATAI","CLCO","CGON","ACM","BMA","AHL","WB","ATKR","BBWI","CRDL","NVDA","NTES","AS","BTBT","ANRO","DLB","AREC","CDLR","ALLT","POWL","ADIL","ZTO","ARMK","DY","CRGO","LGN","AZTA","TGT","BV","ARBE","XP","BZ","BBAR","CRNC","BNTC","CING","ATRA","CPA","ATOS","TCOM","BNZI","DEFT","DE","BRBR","CLSD"],"gpt_icon":1},{"id":"2581588406","title":"Adial Pharmaceuticals Inc  expected to post a loss of 14 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2581588406","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581588406?lang=en_us&edition=fundamental","pubTime":"2025-11-07 23:36","pubTimestamp":1762529764,"startTime":"0","endTime":"0","summary":"Adial Pharmaceuticals Inc  expected to post a loss of14cents a share - Earnings Preview Adial Pharmaceuticals Inc ADIL.OQ ADIL.O is expected to  show no change in quarterly revenue when it reports  re","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nL8N3WJ26E:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADIL","BK4007"],"gpt_icon":0},{"id":"2576204059","title":"Adial Pharmaceuticals CEO was a Featured Guest on The Big Biz Show","url":"https://stock-news.laohu8.com/highlight/detail?id=2576204059","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576204059?lang=en_us&edition=fundamental","pubTime":"2025-10-17 21:00","pubTimestamp":1760706000,"startTime":"0","endTime":"0","summary":"GLEN ALLEN, Va., Oct.  17, 2025  (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies f","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/17/3168634/26135/en/Adial-Pharmaceuticals-CEO-was-a-Featured-Guest-on-The-Big-Biz-Show.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ADIL"],"gpt_icon":0},{"id":"2574106418","title":"Strategic Advancements and Genetic Testing Propel Adial Pharmaceuticals to a Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2574106418","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574106418?lang=en_us&edition=fundamental","pubTime":"2025-10-11 01:15","pubTimestamp":1760116515,"startTime":"0","endTime":"0","summary":"Analyst Jason McCarthy from Maxim Group maintained a Buy rating on Adial Pharmaceuticals and keeping the price target at $1.50. Jason McCarthy has ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/strategic-advancements-and-genetic-testing-propel-adial-pharmaceuticals-to-a-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/strategic-advancements-and-genetic-testing-propel-adial-pharmaceuticals-to-a-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ADIL"],"gpt_icon":0},{"id":"2574579891","title":"Adial Pharmaceuticals partners with Genomind for Precision Medicine Testing","url":"https://stock-news.laohu8.com/highlight/detail?id=2574579891","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574579891?lang=en_us&edition=fundamental","pubTime":"2025-10-09 20:40","pubTimestamp":1760013633,"startTime":"0","endTime":"0","summary":"Adial Pharmaceuticals (ADIL) announced the successful completion of the analytical validation of a cheek swab collection method for testing patient...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/adial-pharmaceuticals-partners-with-genomind-for-precision-medicine-testing-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/adial-pharmaceuticals-partners-with-genomind-for-precision-medicine-testing-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","ADIL"],"gpt_icon":0},{"id":"2571340668","title":"Adial Pharmaceuticals Raised to Buy From Hold by Maxim Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2571340668","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571340668?lang=en_us&edition=fundamental","pubTime":"2025-09-30 20:41","pubTimestamp":1759236060,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ADIL/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  September 30, 2025 08:41 ET (12:41 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADIL"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.adialpharma.com","stockEarnings":[{"period":"1week","weight":-0.2873},{"period":"1month","weight":-0.3853},{"period":"3month","weight":-0.5205},{"period":"6month","weight":-0.5873},{"period":"1year","weight":-0.7989},{"period":"ytd","weight":-0.2873}],"compareEarnings":[{"period":"1week","weight":-0.0133},{"period":"1month","weight":-0.0022},{"period":"3month","weight":0.0237},{"period":"6month","weight":0.0769},{"period":"1year","weight":0.1403},{"period":"ytd","weight":0.0063}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. The company was founded in 2010 and is based in Glen Allen, Virginia.","yearOnYearQuotes":[{"month":1,"riseRate":0.375,"avgChangeRate":0.058856},{"month":2,"riseRate":0.25,"avgChangeRate":0.000821},{"month":3,"riseRate":0,"avgChangeRate":-0.135985},{"month":4,"riseRate":0.428571,"avgChangeRate":-0.019179},{"month":5,"riseRate":0.285714,"avgChangeRate":-0.082775},{"month":6,"riseRate":0.285714,"avgChangeRate":-0.158497},{"month":7,"riseRate":0.571429,"avgChangeRate":0.080123},{"month":8,"riseRate":0.125,"avgChangeRate":-0.073571},{"month":9,"riseRate":0.375,"avgChangeRate":-0.037962},{"month":10,"riseRate":0.25,"avgChangeRate":-0.152838},{"month":11,"riseRate":0.375,"avgChangeRate":0.139286},{"month":12,"riseRate":0.375,"avgChangeRate":0.006709}],"exchange":"NASDAQ","name":"Adial Pharmaceuticals","nameEN":"Adial Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Adial Pharmaceuticals(ADIL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Adial Pharmaceuticals(ADIL) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Adial Pharmaceuticals,ADIL,Adial Pharmaceuticals股票,Adial Pharmaceuticals股票老虎,Adial Pharmaceuticals股票老虎国际,Adial Pharmaceuticals行情,Adial Pharmaceuticals股票行情,Adial Pharmaceuticals股价,Adial Pharmaceuticals股市,Adial Pharmaceuticals股票价格,Adial Pharmaceuticals股票交易,Adial Pharmaceuticals股票购买,Adial Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Adial Pharmaceuticals(ADIL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Adial Pharmaceuticals(ADIL) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}